CLAIMS

- Liposomal formulations comprising at least one active hydrophilic agent encapsulated in liposomes composed of at least one lipid bilayer formed by a mixture of at least one neutral saturated phospholipid and at least one charged saturated lipid.
- Liposomal formulations according to claim 1, characterised in that the neutral saturated phospholipid is chosen from amongst derivatives of phosphatidylcholine and their combinations.
 - 3. Liposomal formulations according to claim 2, characterised in that the derivative of phosphatidylcholine is chosen from amongst DSPC, DPPC and DMPC.
- 4. Liposomal formulations according to claim 1, characterised in that the negatively charged saturated lipid is chosen from amongst a group composed of derivatives of phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, phosphatidic acid and their combinations.
- 5. Liposomal formulations according to claim 4, characterised in that the negatively charged saturated lipid is chosen from amongst DSPG, DPPG and PS.
 - 6. Liposomal formulations according to claim 1, characterised in that the positively charged saturated lipid is SA.
 - 7. Liposomal formulations according to claims 1 to 6, that can also contain at least one other lipid chosen from amongst sterols and derivatives, gangliosides and sphingomyelins.
- 8. Liposomal formulations according to claim 7, characterised in that the sterol is cholesterol.
 - 9. Liposomal formulations according to claim 1 characterised in that the active hydrophilic agent is a drug.

35

25

5

- 10. Liposomal formulations according to claim 9, characterised in that the drug has low molecular weight.
- 11. Liposomal formulations according to claim 10, characterised in that the drug with low molecular weight is selected from amongst 5-fluorouracil, acyclovir, iododeoxyuridine, methotrexate and ciprofloxacin.
 - 12. Liposomal formulations according to the previous claims, comprising 5-FU encapsulated in liposomes composed of DSPC:DSPG.
 - 13. Liposomal formulations according to claims 1 to 11, comprising 5-FU encapsulated in liposomes composed of DSPC:PS.
- 14. Liposomal formulations according to claims 1 to 11, comprising ACV encapsulated in liposomes composed of DPPC:CHOL:DPPG.
 - 15. Liposomal formulations according to claims 1 to 11, comprising ACV encapsulated in liposomes composed of DSPC:DSPG.
- 20 16. Liposomal formulations according to the previous claims, characterised in that the bilayer lipids have a neutral saturated PLs/charged saturated lipid molar ratio between 50/50 and 95/5.
- 17. Liposomal formulations according to claim 16, characterised in that the neutral saturated PLs/charged saturated lipid molar ratio is between 80/20 and 95/5.
 - 18. Liposomal formulations according to the previous claims, characterised in that the active hydrophilic agent/lipids molar ratio is between 0.01/1 and 40/1.
- 19. Liposomal formulations according to claim 18, characterised in that active hydrophilic agent/lipids molar ratio is between 0.1/1 and 2/1.
 - 20. Liposomal formulations according to claims 12, 13, 18 and 19, characterised in that the 5-FU / lipid molar ratio is between 0.2 and 1.5.

35

10

- 21. Liposomal formulations according to claim 20, characterised in that the 5-FU/lipid molar ratio is between 0.5 and 1.0.
- 22. Pharmaceutical formulations that contain liposomal formulations according to any of claims 1 to 21 and a pharmaceutically acceptable vehicle.

5

20

25

- 23. Pharmaceutical formulations according to claim 22, for the topical administration of pharmaceutically active ingredients.
- 24. Use of the formulations according to any of claims 1 to 21, in the preparation of a drug for the prevention and/or treatment of diseases or disorders in humans or animals.
- 25. Use according to claim 24 in which the disease or disorder affects the skin and/or mucous.
 - 26. Use according to claim 25 of a liposomal formulation of 5-FU according to claims 12, 13, 16, 17, 20 or 21 in the preparation of a topical drug for the prevention and/or treatment of hyperproliferative diseases or disorders in the skin and/or mucous.
 - 27. Use according to claim 25 of a liposomal formulation of ACV according to any of claims 14 to 19 in the preparation of a topical drug for the prevention and/or treatment of infections caused by the herpes virus in the skin and/or mucous.
 - 28. Preparation procedures of liposomal formulations according to claims 1 to 21 that includes:
 - Dissolving the lipids in a mixture of organic solvents;
 - Eliminating the solvents until forming a lipid film in the walls of the container;
- Hydrating the film by stirring it with an aqueous solution of the active ingredient;
 - If desired, extract the liposomic suspension formed through filters to select the vesicular size;
 - Subjecting the resulting suspension to diafiltration with a buffer solution;
 - If desired, dilute the liposomic suspension with a buffer solution.